Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 2Phase NA 1Phase 4 1Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 5Head & Neck 4Thoracic 2Dermatologic 2Breast 2Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Multiple Endocrine Neoplasia Type 1 96Pituitary Neoplasms 57Neuroendocrine Tumors 50Thyroid Cancer, Papillary 42Thyroid Neoplasms 16Obesity 15Pheochromocytoma 14Overweight 11Adrenal Gland Neoplasms 10Weight Loss 9Paraganglioma 9Carcinoma, Neuroendocrine 9Pancreatic Neoplasms 8Prostatic Neoplasms 7Motor Activity 7Insulinoma 7Gastrointestinal Neoplasms 7Brain Neoplasms 7Adrenocortical Adenoma 7Acquired Immunodeficiency Syndrome 7Neoplasm Metastasis 6Hyperaldosteronism 6Carcinoma, Medullary 6Stomach Neoplasms 5Osteoporosis 5Neoplasms 5Meningioma 5Liver Neoplasms 5Insulin Resistance 5HIV Infections 5

Interventions

Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Esthesioneuroblastoma, Olfactory × Endocrine × Clear all
NCT00068497 2013-01-14

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase NA Completed
40 enrolled
CNSEndocrineHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Parathyroid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Tongue Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡